Document is current

Any future updates will be listed below

Efficacy and safety of switching to nilotinib in patients with CML-CP in major molecular response to imatinib: results of a multicenter phase II trial (NILSw trial)

Crossref DOI link: https://doi.org/10.1007/s12185-018-2401-y

Published Online: 2018-01-23

Published Print: 2018-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark